Cancer

The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer.  Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

Roche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that

Share

X

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

https://pharmaphorum.com/news/roches-tecentriq-loses-bladder-cancer-use-as-fda-crackdown-continues/

Scotland backs Pfizer’s Ibrance for breast cancer

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced

Share

X

Scotland backs Pfizer’s Ibrance for breast cancer

https://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

A new trial has shown for the first time that a combination of three targeted therapies can improve

Share

X

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/

Puma Biotechnology’s breast cancer drug approved in Europe

Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines

Share

X

Puma Biotechnology’s breast cancer drug approved in Europe

https://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/

Novartis succeeds where Roche failed with PI3K breast cancer drug

Novartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation,

Share

X

Novartis succeeds where Roche failed with PI3K breast cancer drug

https://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/

FDA approves first drug to treat rare adrenal cancer

Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal

Share

X

FDA approves first drug to treat rare adrenal cancer

https://pharmaphorum.com/cancer/fda-approves-first-drug-to-treat-rare-adrenal-cancer/

Accord’s biosimilar Pelgraz poised for approval

Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee

Share

X

Accord’s biosimilar Pelgraz poised for approval

https://pharmaphorum.com/cancer/accords-biosimilar-pelgraz-poised-for-approval/

Fotivda approved in Scotland for kidney cancer

The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma’s kidney cancer drug Fotivda, enabling

Share

X

Fotivda approved in Scotland for kidney cancer

https://pharmaphorum.com/news/fotivda-scotland-kidney-cancer/

Roche to buy rest of genetics firm Foundation Medicine

Roche has made an offer to buy the remaining shares in cancer genetics firm Foundation Medicine (FMI) for

Share

X

Roche to buy rest of genetics firm Foundation Medicine

https://pharmaphorum.com/news/roche-buys-shares-foundation-medicine/